Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) regularly issues news updates that reflect its dual identity as a developmental-stage biopharmaceutical company and a cryptocurrency treasury company. Its press releases highlight progress in drug development for stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, alongside announcements about its evolving digital assets treasury strategy.
On the biopharmaceutical side, Silo’s news flow centers on SPC-15, an investigational intranasal serotonin 5-HT4 receptor agonist being developed for PTSD and stress-induced anxiety. Recent releases describe IND-enabling toxicology and toxicokinetic work, large animal safety studies, drug-device evaluations of a soft mist nasal spray system, and plans for Phase 1 single ascending dose and multiple ascending dose studies. The company also reports on regulatory strategy, including its intention to pursue the FDA’s 505(b)(2) pathway, and on collaborations with organizations such as Allucent and Columbia University.
News items also cover Silo’s broader pipeline, including SP-26 for fibromyalgia and chronic pain and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Investors following SILO news can expect updates on preclinical data, clinical trial preparations, intellectual property expansion, and strategic academic and CRO partnerships.
In parallel, Silo’s releases describe the launch and build-out of its digital assets treasury. Announcements detail initial purchases of Bitcoin, Ethereum, Solana, and ResearchCoin, the establishment of a Crypto Advisory Board, engagement of Fireblocks for institutional-grade custody and infrastructure, and allocation to the Alphaledger T12 Fund for tokenized real-world asset exposure on the Solana blockchain. Additional disclosures include software and domain acquisitions related to crypto applications and updates on treasury diversification objectives.
Visitors to the SILO news page can use this stream of company-issued information to track clinical milestones, regulatory steps, capital markets activity, and digital asset strategy developments over time.
Silo Pharma (Nasdaq: SILO) has secured a new U.S. patent (projected number 12,239,614) for its lead asset SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent, titled 'Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females,' will be issued on March 4, 2025.
This patent builds upon previously issued U.S. Patent 11,491,120 from November 2022, adding new claims and strengthening the company's intellectual property portfolio. The development supports Silo's collaborative research with Columbia University and advances their efforts toward clinical trials for SPC-15.
Silo Pharma (NASDAQ: SILO) has filed a new provisional patent application with the USPTO for its lead asset SPC-15, expanding its intellectual property portfolio. The patent covers a dual-action method and composition for treating stress-induced psychiatric disorders.
A preclinical study demonstrated that the combination of SPC-15, a serotonin type IV receptor (5-HT4R) agonist, with an N-methyl-D-aspartate receptor (NMDAR) antagonist showed significant improvements in behavioral outcomes and reduced severe stress-induced conditions. This technology was originally licensed through a collaboration with Columbia University.
The company has also recently filed a separate expanded provisional patent application focusing on chronic, combinatorial targeting of NMDARs and 5-HT4Rs to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia.
Silo Pharma (NASDAQ: SILO) reported positive initial results from its ongoing study of SP-26, a novel ketamine extended-release rod implant designed for chronic pain and fibromyalgia treatment. The non-GLP small animal testing, which began in December 2024, showed no serious side effects or discomfort following implantation in early January 2025.
The SP-26 implant is being developed as a self-administered, non-opioid therapeutic. The study is currently in the final stages of Absorption, Distribution, Metabolism, and Excretion (ADME) testing, with final safety and pharmacokinetic reports expected in March 2025.
Silo Pharma (NASDAQ: SILO) has filed a provisional patent application with the USPTO for its lead asset SPC-15, targeting treatments for stress-induced psychiatric disorders, including PTSD. The patent covers the chronic, combinatorial targeting of N-methyl-D-aspartate receptors (NMDARs) and serotonin type IV receptors (5-HT4Rs) to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia.
This filing enhances Silo's intellectual property portfolio for SPC-15 technology, which was originally licensed through a collaboration with Columbia University. The exclusive agreement grants Silo global rights to develop, manufacture, and commercialize SPC-15.
Silo Pharma (NASDAQ: SILO) has received a Notice of Allowance from the USPTO for patent application 17/954,864, titled 'Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.' This patent, expected to be formally issued within 90 days, will strengthen protection for SPC-15, the company's lead asset targeting post-traumatic stress disorder (PTSD) through intranasal delivery.
The patent includes new claims to U.S. Patent 11,491,120, which was issued to Silo in February 2023. The company holds an exclusive license agreement with Columbia University for global development, manufacturing, and commercialization rights of SPC-15, including extensive issued patents and pending IP patent applications.
Silo Pharma (NASDAQ: SILO) has issued a shareholder letter highlighting progress on its lead assets. The company plans to submit an IND application for SPC-15, an intranasal PTSD treatment, in 2025, followed by Phase 1 clinical trials. SPC-15 has shown promising pre-clinical results for PTSD, stress, and potentially eating disorders.
The company is also advancing SP-26, a ketamine implant for fibromyalgia and chronic pain, with animal testing scheduled for early 2025. Both drugs could qualify for the FDA's streamlined 505(b)(2) regulatory pathway, potentially accelerating approval timelines.
Silo has exclusive global rights to commercialize SPC-15 through a collaboration with Columbia University. The company reports a strong balance sheet with minimal debt as it advances its development programs.
Silo Pharma (NASDAQ: SILO) has initiated a pharmacokinetic (PK) and tolerability study for SP-26, its dissolvable ketamine-based injectable implant targeting chronic pain and fibromyalgia. The three-week non-GLP study, conducted in partnership with AmplifyBio, will evaluate the absorption, distribution, metabolism, and excretion of extended-release ketamine hydrochloride implants in a minipig model. Two different polymer formulations will be tested at various dose levels.
This milestone follows several previous studies including analytical testing, proof-of-concept extrusion trials, manufacturing evaluation, and sterilization tests. SP-26 is being developed as a self-administered, non-opioid therapeutic and aims to be a first-of-its-kind ketamine treatment for chronic pain.
Silo Pharma (SILO) has entered a collaboration agreement with Kymanox to develop a subcutaneous insertion device for SP-26, their ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. The agreement includes initial proof-of-concept design followed by prototype development and feasibility testing to determine optimal tissue insertion depth. Previous testing has confirmed the optimal formulation for SP-26 implants. The company aims to develop SP-26 as a potential first-in-class at-home injectable ketamine-based therapeutic, with preclinical research focusing on FDA safety requirements. Kymanox also serves as Silo's regulatory partner for SPC-15, a treatment for stress-induced affective disorders including PTSD.
Silo Pharma (NASDAQ: SILO) announced positive preclinical study results for SPC-15, a novel dual-action treatment targeting stress-related disorders. The study combined SPC-15, a 5-HT4R agonist, with an NMDAR antagonist, demonstrating enhanced efficacy in treating stress-induced behaviors compared to single-agent treatments. The research showed significant improvements in behavioral outcomes related to severe stress-induced conditions in animal models. The company is developing SPC-15 as an intranasal prophylactic treatment for PTSD and plans to submit an IND for first-in-human trials.
Silo Pharma (SILO) announced positive results from sterilization and dissolution tests of its SP-26 ketamine-loaded implant for fibromyalgia and chronic pain. The tests, conducted under a development agreement with Sever Pharma Solutions, showed the implant achieved over 80% drug release over a 7-day period with consistent delivery. The implants demonstrated minimal variation in physical properties, indicating safety and stability. The company plans to proceed with animal studies to evaluate the efficacy of these dose-controlled, time-release implants for fibromyalgia and chronic pain treatment.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
